⏳ Compounding Update: The FDA has delayed enforcement on 503A pharmacies until a court ruling expected by February 25.

🔬 Fat Cell Research: New findings suggest fat cells may help tailor obesity treatments based on individual profiles.

💊 PBM Concerns: Advocacy for Pharmacy Benefit Manager reform highlights their impact on drug prices and patient access.

📈 Investor Insights: Amalin shows promise in obesity treatment, with new research indicating its effects on appetite and food choices.

🏥 Upcoming Medications: Kagema is anticipated to hit the market in early 2026, alongside new developments from various companies.

🎉 Community Engagement: The podcast encourages listeners to subscribe and support ongoing efforts in obesity medicine discussions